1. Home
  2. BYFC vs MAIA Comparison

BYFC vs MAIA Comparison

Compare BYFC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Broadway Financial Corporation

BYFC

Broadway Financial Corporation

N/A

Current Price

$9.60

Market Cap

79.2M

Sector

Finance

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.38

Market Cap

77.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BYFC
MAIA
Founded
1946
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
77.1M
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
BYFC
MAIA
Price
$9.60
$1.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.5K
495.3K
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
0.05
N/A
Revenue
$184,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$190.80
N/A
Revenue Growth
18.71
N/A
52 Week Low
$5.51
$0.87
52 Week High
$10.46
$3.19

Technical Indicators

Market Signals
Indicator
BYFC
MAIA
Relative Strength Index (RSI) 58.89 55.69
Support Level $7.17 $1.23
Resistance Level $10.46 $1.46
Average True Range (ATR) 0.14 0.08
MACD -0.10 0.01
Stochastic Oscillator 27.92 89.19

Price Performance

Historical Comparison
BYFC
MAIA

About BYFC Broadway Financial Corporation

Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: